Vaxcyte Inc. (PCVX)
NASDAQ: PCVX
· Real-Time Price · USD
29.31
-0.74 (-2.46%)
At close: May 14, 2025, 1:47 PM
Vaxcyte Revenue Breakdown
| Period Ending | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|
| Pneumococcal Conjugate Vaccine Revenue | 7B | 7B |
| Pneumococcal Conjugate Vaccine Revenue Growth | 0.00% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 32.66M | 28.55M | 22.99M | 18M | 19.89M | 14.58M | 15.61M | 14.46M | 13.11M | 11.95M | 10.9M | 9.42M | 7.54M | 6.77M | 6.52M | 6.08M | 5.88M | 4.79M | 4.9M | 3.05M | 3.28M | 2.46M | 2.51M | 2.26M | 1.32M |
| Selling, General, and Administrative Revenue Growth | +14.37% | +24.22% | +27.74% | -9.50% | +36.40% | -6.58% | +7.95% | +10.25% | +9.71% | +9.67% | +15.73% | +24.84% | +11.39% | +3.82% | +7.30% | +3.30% | +22.81% | -2.16% | +60.80% | -7.16% | +33.54% | -2.11% | +10.87% | +72.04% | n/a |
| Research and Development Revenue | 148.13M | 133.61M | 116.94M | 131.51M | 94.59M | 104.15M | 97.42M | 72.69M | 58.08M | 51.63M | 47.68M | 38.47M | 31.68M | 23.07M | 20.43M | 17.65M | 17.26M | 14.66M | 16.41M | 18.18M | 24.32M | 13.38M | 9.63M | 9.97M | 12.63M |
| Research and Development Revenue Growth | +10.87% | +14.26% | -11.08% | +39.03% | -9.18% | +6.91% | +34.02% | +25.16% | +12.50% | +8.28% | +23.94% | +21.44% | +37.29% | +12.95% | +15.73% | +2.28% | +17.71% | -10.66% | -9.73% | -25.24% | +81.70% | +38.96% | -3.39% | -21.06% | n/a |